Claims for Patent: 11,083,724

Summary for Patent: 11,083,724

Title:	Rimegepant for CGRP related disorders
Abstract:	Disclosed are methods of treating CGRP related disorders, e.g., migraine, by administering to a patient in need thereof rimegepant or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising rimegepant and kits including the pharmaceutical compositions and instructions are also disclosed.
Inventor(s):	Coric; Vladimir (Madison, CT), Croop; Robert (Newton Square, PA)
Assignee:	Biohaven Pharmaceutical Ireland DAC (Dublin, IE)
Application Number:	16/884,196
Patent Claims:	1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a CGRP receptor antagonist, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition is in a form of an oral solid molded fast-dispersing dosage form. 2. The pharmaceutical composition of claim 1, wherein the CGRP receptor antagonist is selected from olcegepant, telcagepant, ubrogepant, atogepant, and rimegepant. 3. The pharmaceutical composition of claim 1, further comprising gelatin as a carrier. 4. The pharmaceutical composition of claim 1, further comprising mannitol as a filler. 5. The pharmaceutical composition of claim 1, comprising from about 70-80 weight % of the CGRP antagonist, about 10-20 weight % fish gelatin, about 10-20 weight % of a filler, and 0.1-5.0 weight % of a flavorant. 6. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is capable of disintegrating or dispersing within an interval selected from 1 to 60 seconds, 1 to 30 seconds, 1 to 10 seconds, and 2 to 8 seconds, after being placed in contact with a fluid. 7. The pharmaceutical composition of claim 6, wherein the fluid comprises saliva. 8. A method of treating migraine in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a CGRP receptor antagonist, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition is in a form of an oral solid molded fast-dispersing dosage form. 9. The method of claim 8, wherein the CGRP receptor antagonist is selected from olcegepant, telcagepant, ubrogepant, atogepant, and rimegepant. 10. The method of claim 8, comprising from about 70-80 weight % of the CGRP antagonist, about 10-20 weight % fish gelatin, about 10-20 weight % of a filler, and 0.1-5.0 weight % of a flavorant. 11. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of rimegepant, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical composition is in a form of an oral solid molded fast-dispersing dosage form. 12. The pharmaceutical composition of claim 11, comprising about 75 mg of rimegepant or a pharmaceutically acceptable salt thereof. 13. The pharmaceutical composition of claim 11, wherein the rimegepant is in the form of a hemisulfate sesquihydrate salt. 14. The pharmaceutical composition of claim 11 in the form of a tablet. 15. The pharmaceutical composition of claim 11, that provides an AUC.sub.0-t of from about 80-125% of 5000 (hr*ng/mL). 16. The pharmaceutical composition of claim 11, comprising from about 70-80 wt % rimegepant hemisulfate sesquihydrate, about 10-20 wt % fish gelatin, about 10-20 wt % of a filler, and 0.1-5.0 wt % of a flavorant. 17. The pharmaceutical composition of claim 11, further comprising gelatin as a carrier. 18. The pharmaceutical composition of claim 11, further comprising mannitol as a filler. 19. The pharmaceutical composition of claim 11, wherein the pharmaceutical composition is capable of disintegrating or dispersing within an interval selected from 1 to 60 seconds, 1 to 30 seconds, 1 to 10 seconds, and 2 to 8 seconds, after being placed in contact with a fluid. 20. The pharmaceutical composition of claim 19, wherein the fluid comprises saliva.